Terumo Corporation today celebrates the 90th anniversary of the company’s founding in 1921. Terumo Corporation is one of the world’s leading medical device manufacturers with $4 billion in annual sales and operations in more than 160 countries.
In August, Forbes magazine ranked Terumo Corporation 14th of the top 100 global companies on its “World’s Most Innovative Companies” list. According to Forbes, the rankings were based on findings from an eight year study led by a team of independent industry researchers who assessed each company’s “innovation premium,” a measure of investor expectation for future innovation such as new product development, services and market development.
For 90 years, medical professionals have trusted Terumo Corporation because the company’s deep understanding of practical, clinical, and economic needs has led to insightful, ‘people-friendly’ solutions that contribute to better patient outcomes. The company is grateful to its customers and Associates worldwide who are the driving force behind Terumo Corporation’s strong, long-term stability and evolution as a leader in global healthcare.
Originally founded in Japan by several medical scientists intent on manufacturing the most reliable clinical thermometers, Terumo Corporation has evolved into a global leader in the development, manufacture, and distribution of world-class medical devices in high-growth therapeutic areas of cardiovascular medicine such as cardiothoracic surgery, left-ventricular assist systems for end-stage heart failure, minimally invasive coronary and endovascular interventions, and neuro-interventional technologies for cerebral aneurysms.
In 2011, Terumo strengthened its global portfolio with strategic acquisitions of CaridianBCT and Harvest Technologies Corp. The acquisition of CaridianBCT elevates Terumo as the leader in blood processing technology, while Harvest Technologies provides access to the world’s first point-of-care technology allowing physicians to derive highly concentrated autologous, adult stem cells from bone marrow that international human clinical studies have shown are highly effective in treating vascular, orthopedic and cardiovascular diseases.
Terumo Corporation’s mission is to contribute to the evolution of healthcare by maintaining close communication with customers worldwide. The company will continue to execute a comprehensive business strategy that combines innovative medical device technology with extensive educational and training support for healthcare professionals worldwide.
Tokyo-based Terumo Corporation is one of the world’s leading medical device manufacturers with $4 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures, and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use.
Terumo contributes to society by providing valued products and services to the healthcare market and by responding to the needs of healthcare providers and the people they serve. Terumo Corporation’s shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan’s leading stock index.